Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation

Arthritis and Rheumatism

Volumn 58, Issue 5, 2008, Pages 1216-1219

  Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CALCINEURIN INHIBITOR; CALCIUM; CALCIUM CHANNEL; CHELATING AGENT; CYCLOSPORIN; F ACTIN; FC RECEPTOR; GLUTAMIC ACID; IMMUNOGLOBULIN E; LANTHANUM; PHOSPHOLIPASE C GAMMA1; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; PROTEIN KINASE SYK; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THAPSIGARGIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; CALCIUM SIGNALING; DENDRITIC CELL; DRUG EFFECT; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; HUMAN; LYMPHOCYTE; MACROPHAGE; NATURAL KILLER T CELL; ORAI1 GENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES;

EID: 43949111674     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23445     Document Type: Editorial

References (22)

1. Gallo EM, Cante-Barrett K, Crabtree GR. Lymphocyte calcium signaling from membrane to nucleus. Nat Immunol 2006;7:25-32.
2. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995;155:2269-81.
3. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98:2549-57.
4. Poulopoulou C, Papadopoulou-Daifoti Z, Hatzimanolis A, Fragiadaki K, Polissidis A, Anderzanova E, et al. Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus. Arthritis Rheum 2008;58:1445-50.
5. Feske S. Calcium signalling in lymphocyte activation and disease [review]. Nat Rev Immunol 2007;7:690-702.
6. Vig M, Kinet JP. The long and arduous road to CRAC. Cell Calcium 2007;42:157-62.
7. 2+ entry. Science 2006;312:1220-3.
8. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006;441:179-85.
9. De la Fuente MA, Sasahara Y, Calamito M, Anton IM, Elkhal A, Gallego MD, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A 2007;104: 926-31.
10. + channels in human T lymphocytes: a role in mitogenesis? Nature 1984;307:465-8.
11. + channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. Am J Physiol Cell Physiol 2007;292:C1431-9.
12. Crispin JC, Kyttaris VC, Juang YT, Tsokos GC. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 2008. E-pub ahead of print.
13. + signaling profile of lupus T cells. J Immunol 2004;173:3676-83.
14. Nicolaou SA, Szigligeti P, Neumeier L, Lee SM, Duncan HJ, Kant SK, et al. Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus. J Immunol 2007;179:346-56.
15. Enyedy EJ, Mitchell JP, Nambiar MP, Tsokos GC. Defective FcγRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol 2001;101:130-5.
16. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, et al. Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J Exp Med 2006;203:2157-64.
17. Soares L, Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD, et al. Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immunol 2004;5:45-54.
18. 2+ entry and NFAT activation in lymphocytes. Cell Calcium 2007;42:145-56.
19. Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol 2007;178:1960-6.
20. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005;115:996-1005.
21. Bahjat R, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58:1433-44.
22. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005;67:1369-81.